U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13N3O4S.H2O
Molecular Weight 349.362
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIROXICAM MONOHYDRATE

SMILES

O.CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CC=C3)S1(=O)=O

InChI

InChIKey=SDJQUPRVYCURBW-UHFFFAOYSA-N
InChI=1S/C15H13N3O4S.H2O/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22;/h2-9,19H,1H3,(H,16,17,20);1H2

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.pfizermedicalinformation.com/en-us/feldene

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.

CNS Activity

Originator

Pfizer
420
Curator's Comment: originally brought to market by Pfizer under the tradename Feldene in 1980 # Pfizer

Approval Year

1982
100
Targets

Targets

Primary TargetPharmacologyConditionPotency
Catalase
6
Target ID: P04040
Gene ID: 847.0
Gene Symbol: CAT
Target Organism: Homo sapiens (Human)
Inhibitor
8297
 0.414 mM [IC50]
Inhibitor
8297
 4.4 µM [IC50]
Inhibitor
8297
 70.0 µM [IC50]
Inhibitor
8297
 73.8 µM [IC50]
Inhibitor
8297
 7.0 µM [IC50]
Inhibitor
8297
 1.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
FELDENE

Approved Use

FELDENE is a nonsteroidal anti-inflammatory drug indicated for Relief of the signs and symptoms of osteoarthritis (OA) Relief of the signs and symptoms of rheumatoid arthritis (RA)

Launch Date

1982
Primary
Approved
8429
FELDENE

Approved Use

FELDENE is a nonsteroidal anti-inflammatory drug indicated for Relief of the signs and symptoms of osteoarthritis (OA) Relief of the signs and symptoms of rheumatoid arthritis (RA)

Launch Date

1982
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.3 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27129120
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIROXICAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
135.8 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27129120
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIROXICAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.5 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27129120
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIROXICAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Disc. AE: Chest pain, Rash...
AEs leading to
discontinuation/dose reduction:
Chest pain (0.74%)
Rash (0.74%)
Vomiting (0.74%)
Exanthema (0.74%)
Injection site pain (0.74%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
1800 mg single, oral
Overdose
Dose: 1800 mg
Route: oral
Route: single
Dose: 1800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
unhealthy, 54
n = 1
Health Status: unhealthy
Condition: Arthralgia
Age Group: 54
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
Disc. AE: Nausea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Nausea
Abdominal pain
Gastric ulcer
Duodenal ulcer
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Disc. AE: Gastrointestinal disorders, Haemorrhage of digestive tract...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders (2.6%)
Haemorrhage of digestive tract (0.85%)
Headache (0.85%)
Oedema (0.85%)
Pruritus (0.85%)
Erythema facial (0.85%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
unhealthy, >40
n = 40
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: >40
Sex: M+F
Population Size: 40
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
Disc. AE: Epigastric discomfort, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Epigastric discomfort (2.5%)
Diarrhoea (2.5%)
Loose stools (2.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Disc. AE: Cardiac thrombosis, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Cardiac thrombosis (grade 3-5)
Myocardial infarction (grade 3-5)
Stroke (grade 3-5)
Gastrointestinal disorder NOS (serious)
Bleeding (serious)
Ulceration (serious)
Perforation stomach (grade 3-5)
Perforation of intestine (grade 3-5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Chest pain 0.74%
Disc. AE
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Exanthema 0.74%
Disc. AE
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Injection site pain 0.74%
Disc. AE
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Rash 0.74%
Disc. AE
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Vomiting 0.74%
Disc. AE
40 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
unhealthy, 19 -74
n = 135
Health Status: unhealthy
Condition: Acute sprains|Tendinitis| Low back pain
Age Group: 19 -74
Sex: M+F
Population Size: 135
Sources:
https://pubmed.ncbi.nlm.nih.gov/2932357
Page: p.260
Abdominal pain Disc. AE
1800 mg single, oral
Overdose
Dose: 1800 mg
Route: oral
Route: single
Dose: 1800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
unhealthy, 54
n = 1
Health Status: unhealthy
Condition: Arthralgia
Age Group: 54
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
Duodenal ulcer Disc. AE
1800 mg single, oral
Overdose
Dose: 1800 mg
Route: oral
Route: single
Dose: 1800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
unhealthy, 54
n = 1
Health Status: unhealthy
Condition: Arthralgia
Age Group: 54
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
Gastric ulcer Disc. AE
1800 mg single, oral
Overdose
Dose: 1800 mg
Route: oral
Route: single
Dose: 1800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
unhealthy, 54
n = 1
Health Status: unhealthy
Condition: Arthralgia
Age Group: 54
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
Nausea Disc. AE
1800 mg single, oral
Overdose
Dose: 1800 mg
Route: oral
Route: single
Dose: 1800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
unhealthy, 54
n = 1
Health Status: unhealthy
Condition: Arthralgia
Age Group: 54
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6496192
Erythema facial 0.85%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Haemorrhage of digestive tract 0.85%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Headache 0.85%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Oedema 0.85%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Pruritus 0.85%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Gastrointestinal disorders 2.6%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
unhealthy, 59.7+/-7.4
n = 117
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: 59.7+/-7.4
Sex: M+F
Population Size: 117
Sources:
https://pubmed.ncbi.nlm.nih.gov/9093797
Page: p.158
Diarrhoea 2.5%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
unhealthy, >40
n = 40
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: >40
Sex: M+F
Population Size: 40
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
Epigastric discomfort 2.5%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
unhealthy, >40
n = 40
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: >40
Sex: M+F
Population Size: 40
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
Loose stools 2.5%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
unhealthy, >40
n = 40
Health Status: unhealthy
Condition: Osteoarthritis
Age Group: >40
Sex: M+F
Population Size: 40
Sources:
https://pubmed.ncbi.nlm.nih.gov/2202544
Page: p.233
Cardiac thrombosis grade 3-5
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Myocardial infarction grade 3-5
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Perforation of intestine grade 3-5
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Perforation stomach grade 3-5
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Stroke grade 3-5
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Bleeding serious
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Gastrointestinal disorder NOS serious
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Ulceration serious
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Osteoarthritis|Rheumatoid arthritis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1037

inhibitor
1767
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT1
599

OAT2
145

OAT3
642

OAT4
146

Nav1.5
97
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT1
603
 yes [Ki 20.5 uM]
CYP2C9
1819
 yes [Ki 23 uM]
OAT3
644
 yes [Ki 4.88 uM]
OAT2
147
 yes [Ki 70.3 uM]
OAT4
146
 yes [Ki 84.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1037
 major
yes (pharmacogenomic study)
Comment: Higher systemic exposure of piroxicam has been noted in subjects with CYP2C9 polymorphisms compared to normal metabolizer type subject
CYP3A4
1737
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Nav1.5
100
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8249
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8249
ChemicalBook
CB1375282
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1375282
MolPort
MolPort-001-888-120
https://www.molport.com/shop/molecule-link/MolPort-001-888-120
Selleck Chemicals
Piroxicam(Feldene)
http://www.selleckchem.com/products/Piroxicam(Feldene).html
ZINC
ZINC000051133897
http://zinc15.docking.org/substances/ZINC000051133897
eMolecules
593185
https://www.emolecules.com/cgi-bin/more?vid=593185
PubMed

PubMed

TitleDatePubMed
Piroxicam-induced renal failure.
1983 Nov
Piroxicam-induced renal disease.
1984 Jan
Piroxicam-induced acute renal failure (anuria).
1985 May
[Acute hemolytic anemia and hepatonephritis caused by piroxicam].
1988 Oct-Dec
Piroxicam-induced renal failure following relief of chronic retention.
1989 Apr
Aplastic anaemia associated with piroxicam.
1991 Feb
A comparison of tenoxicam and piroxicam in the treatment of rheumatoid arthritis.
1992 Apr
Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study.
1993 May-Jun
Renal disease and use of topical non-steroidal anti-inflammatory drugs.
1994 Jan 8
Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone.
1995 Oct
Tenidap inhibits replication of the human immunodeficiency virus-1 in cultured cells.
1997 Jan 1
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
1997 Mar 14
Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice.
1998 Apr
[Cholestatic hepatitis associated with piroxicam use. Case report].
1998 May
Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
1999 Apr
Recurrent aseptic meningitis following non- steroidal anti-inflammatory drugs--a reminder.
1999 Dec
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
1999 Jun
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.
1999 May
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
1999 May 7
A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.
1999 Nov
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000 Aug
Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice.
2000 Dec
[Drug-induced toxic hearing loss (piroxicam and natural sulfo-conjugated estrogens): apropos of 2 case reports ].
2001
Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease.
2001 Apr
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
2002 Apr
[Acute hepatic and renal failure due to piroxicam use].
2002 Mar
The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study.
2002 Mar 1
Protective role of cyclooxygenase (COX) inhibitors in burn-induced intestinal and liver damage.
2002 May
Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs.
2002 Oct 11
Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents.
2002 Sep
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
2003 Jan 1
Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
2003 Jul
[Generalized angioedema with capillary leak syndrome after piroxicam use: a case].
2003 Sep-Oct
Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
2004 Jul 15
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.
2004 Jun
Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.
2005 Jul
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.
2005 Jul 14
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
2005 May
Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes.
2005 Nov
The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
2005 Sep
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Piroxicam: restriction of indications: labelling change. Only half-measures.
2008 Oct
Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.
2009
The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells.
2009 Apr
Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats.
2010 Feb
The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1.
2010 Mar
Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice.
2011 Jun 10
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

JP2000327588A
6
JP2000501709A
75
JP2001039876A
13
JP2001503372A
27
JP2001525058A
70
JP2002128674A
4
JP2002128698A
5
JP2002193793A
4
JP2002511777A
414
JP2002513391A
22
JP2002521487A
13
JP2002528495A
37
JP2002533379A
53
JP2002541233A
400
JP2002544210A
89
JP2003252764A
4
JP2003503407A
8
JP2003515526A
462
JP2003528044A
30
JP2004175723A
8
JP2004269528A
28
JP2004523497A
81
JP2004534728A
78
JP2004534833A
5
JP2004536811A
36
JP2005525136A
34
JP2005535563A
67
JP2006500966A
34
JP2006506376A
4
JP2006515994A
12
JP2006523687A
29
JP2006524634A
46
JP2007238593A
4
JP2007503428A
35
JP2007508039A
114
JP2007508391A
16
JP2007512273A
10
JP2007513165A
55
JP2007514746A
8
JP2007514770A
75
JP2007515489A
13
JP2008504356A
31
JP2008505724A
4
JP2008539832A
82
JP2009525778A
32
JP2009525790A
101
JP2009533455A
12
JP2010506837A
76
JP2010525083A
52
JP2011006465A
4
JP2011500184A
34

Sample Use Guides

In Vivo Use Guide
Recommended dose: 20 mg orally once a day
Route of Administration: Oral
In Vitro Use Guide
Contractions induced by bradykinin in guinea-pig gallbladder smooth muscle strips were significantly attenuated by the cyclooxygenase inhibitor piroxicam (10 muM).
Name Type Language
PIROXICAM MONOHYDRATE
Common Name English
2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-, 1,1-DIOXIDE, HYDRATE (1:1)
Systematic Name English
2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-, 1,1-DIOXIDE, MONOHYDRATE
Systematic Name English
Code System Code Type Description
PUBCHEM
54705052
Created by admin on Sat Dec 16 07:44:08 GMT 2023 , Edited by admin on Sat Dec 16 07:44:08 GMT 2023
PRIMARY
CAS
90936-70-2
Created by admin on Sat Dec 16 07:44:08 GMT 2023 , Edited by admin on Sat Dec 16 07:44:08 GMT 2023
PRIMARY
FDA UNII
28MQO4N66D
Created by admin on Sat Dec 16 07:44:08 GMT 2023 , Edited by admin on Sat Dec 16 07:44:08 GMT 2023
PRIMARY
EPA CompTox
DTXSID00238326
Created by admin on Sat Dec 16 07:44:08 GMT 2023 , Edited by admin on Sat Dec 16 07:44:08 GMT 2023
PRIMARY
PARENT (SALT/SOLVATE)
Structure of PIROXICAM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966